Lonsurf (trifluridine/tipiracil) / Otsuka 
Welcome,         Profile    Billing    Logout  
 6 Diseases   125 Trials   125 Trials   2571 News 


12345678910111213...3334»
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka, Avastin (bevacizumab) / Roche
    Review, Journal:  Trifluridine/tipiracil regimen in combination with bevacizumab for metastatic colorectal cancer in the third line: an expert opinion. (Pubmed Central) -  Feb 6, 2025   
    Based on a critical review of the literature aimed to guide clinicians in their daily decision-making, we point out that the combination of FTD/TPI with bevacizumab produces a clinical benefit in unselected mCRC patients. Therefore, the FTD/TPI plus bevacizumab regimen can represent a new standard of care for the treatment of patients with refractory mCRC who have progressed after two lines of therapy.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka, Fruzaqla (fruquintinib) / Takeda, Stivarga (regorafenib) / Bayer
    Retrospective data, Journal:  Rechallenge therapy versus tyrosine kinase inhibitor (TKI) for advanced metastatic colorectal cancer: a retrospective study. (Pubmed Central) -  Feb 5, 2025   
    Furthermore, subgroup analysis showed that in Group A, the rechallenge group also had superior median OS and PFS compared with the TKI group. In conclusion, while TKIs are the current standard for third-line treatment in mCRC patients, chemotherapy rechallenge is a more effective option for patients who have achieved disease control in the first two lines of treatment.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka
    Journal:  Trifluridine/Tipiracil (FTD/TPI) in Metastatic Colorectal Cancer in Hong Kong: A Territory-Wide Cohort Study. (Pubmed Central) -  Feb 1, 2025   
    Our data show that treatment with FTD/TPI offers survival benefits in patients with refractory mCRC in Hong Kong consistent with randomized controlled trials and other real-world studies. Furthermore, the prognosis in patients receiving FTD/TPI appears to be significantly better in those who develop neutropenia, with RAS wild-type status, or those without liver metastases, despite a higher rate of dose reduction in the real-world setting.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka, Keytruda (pembrolizumab) / Merck (MSD)
    Enrollment open, Phase classification:  Phase II Study of Pembrolizumab and Trifluridine/Tipiracil with Previously Treated Advanced Gastric Cancer (clinicaltrials.gov) -  Dec 27, 2024   
    P1/2,  N=75, Recruiting, 
    This could allow for the extension of mCRC treatment choices until prospective studies are finished or randomised trials are performed. Not yet recruiting --> Recruiting | Phase classification: P2 --> P1/2
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka, Opdivo (nivolumab) / BMS
    Clinical data, Review, Journal, Adverse events:  Pharmacist intervention and identification of adverse events related to treatment efficacy in cancer chemotherapy to improve clinical outcomes. (Pubmed Central) -  Dec 19, 2024   
    Incidence of hypomagnesemia in patients receiving anti-EGFR antibodies and neutropenia in patients receiving TAS-102 was significantly associated with the therapeutic effect of cancer chemotherapy...In patients receiving nivolumab, the presence of cancer cachexia prior to treatment initiation was associated with shorter OS and TTF...Further, AEs which are predictive of treatment response in cancer chemotherapy were identified. Management of these AEs is an important role for pharmacists aiming to improve patient QOL and treatment efficacy.
  • ||||||||||  Review, Journal, Metastases:  Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm. (Pubmed Central) -  Dec 18, 2024   
    In this Review, we provide a comprehensive overview of advances in the field over the past few years and offer a practical perspective on translation of the most relevant results into the daily management of patients with metastatic colorectal cancer using an evidence-based algorithm. Finally, we discuss some of the most appealing ongoing areas of research and highlight approaches with the potential to further expand the therapeutic armamentarium.
  • ||||||||||  FOG-001 / FogPharma
    Enrollment change:  FOG-001-101: FOG-001 in Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) -  Dec 18, 2024   
    P1/2,  N=480, Recruiting, 
    Finally, we discuss some of the most appealing ongoing areas of research and highlight approaches with the potential to further expand the therapeutic armamentarium. N=245 --> 480
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka, Avastin (bevacizumab) / Roche
    A retrospective observational study to evaluate the efficacy of trifluridine/tipiracil  (Level 1, West Hall; Poster Bd #: F13) -  Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_814;    
    The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka, Talzenna (talazoparib) / Pfizer
    Synergistic Effect of Trifluridine and PARPi Combination in Targeting TP53-Mutated AML () -  Dec 7, 2024 - Abstract #ASH2024ASH_7867;    
    However, CI values for this combination ranged from 1.03-9.30 in cells with TP53-WT cell lines implying antagonism.Conclusions : These results, for the first time, demonstrate synergism between TAS-102 and talazoparib to specifically target and mediate cytotoxicity in a panel of AML cell lines with TP53 mutations but not those with wildtype TP53. Ongoing studies are focused on testing these in primary patient specimens and PDX mouse models, once validated these results support the potential for using this two-drug combination of FDA-approved drugs for improving outcome in TP53-mutated AML.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka
    P1/2 data, Journal, Metastases:  Phase I/II study of trifluridine/tipiracil plus XB2001 versus trifluridine/tipiracil in metastatic colorectal cancer. (Pubmed Central) -  Nov 30, 2024   
    P1/2
    We aim to assess the addition of XB2001 (anti-IL-1 alpha monoclonal antibody) plus trifluridine/tipiracil-bevacizumab in mCRC refractory to standard chemotherapy. This multicenter, randomized, double blind, non-comparative Phase I-II study (ClinicalTrials.gov NCT05201352) will assess the efficacy and safety of trifluridine/tipiracil-bevacizumab and XB2001 in patients with mCRC previously treated for metastatic disease by chemotherapy treatment including oxaliplatin, irinotecan, 5-FU, antiangiogenic and/or anti-EGFR if indicated...Primary end point of Phase II is the efficacy of trifluridine/tipiracil-bevacizumab
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka, Avastin (bevacizumab) / Roche
    Journal, HEOR, Monotherapy, Cost-effectiveness, Cost effectiveness:  Cost-effectiveness analysis of trifluridine/tipiracil combined with bevacizumab vs. monotherapy for third-line treatment of colorectal cancer. (Pubmed Central) -  Nov 28, 2024   
    This multicenter, randomized, double blind, non-comparative Phase I-II study (ClinicalTrials.gov NCT05201352) will assess the efficacy and safety of trifluridine/tipiracil-bevacizumab and XB2001 in patients with mCRC previously treated for metastatic disease by chemotherapy treatment including oxaliplatin, irinotecan, 5-FU, antiangiogenic and/or anti-EGFR if indicated...Primary end point of Phase II is the efficacy of trifluridine/tipiracil-bevacizumab Probabilistic sensitivity analysis further confirmed the robustness of the results, showing that at a willingness-to-pay threshold of
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka, uridine triacetate (PN 401) / Wellstat, roducitabine (PCS3117) / Processa Pharma
    Journal:  Nucleo(s)tide metabolism as basis for drug development; the Anne Simmonds award lecture. (Pubmed Central) -  Nov 21, 2024   
    The combination of 5FU with uridine, led to the development of triacetyluridine registered for emergency treatment of patients with lethal 5FU toxicity...The latter actually led to the most interesting results. Investigation of (nucleoside/nucleotide) metabolism remains an exciting field of research.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka
    Trial completion date, Combination therapy, Metastases:  TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer (clinicaltrials.gov) -  Nov 18, 2024   
    P2,  N=50, Active, not recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Mar 2024 --> Mar 2026